Purpose of this Study
We are doing this study to find out if an experimental drug called CTX131 (the study drug) is a safe and effective treatment for different forms of cancer with solid tumors. The study drug is made from white blood cells or T cells from healthy donors.
Who Can Participate?
Eligibility
Adults ages 18+ who:
Are diagnosed with clear cell renal carcinoma (ccRCC), cervical carcinoma (CC), esophageal carcinoma (EC), pancreatic adenocarcinoma (PAC), or malignant pleural mesothelioma (MPM)
Have received at least one round of previous treatment
Have never received treatment with anti-CD70 targeting agents
For more information about who can join this study, please contact the study team at 919-681-6468.
What is Involved?
Description
If you choose to join this study, you will:
- Receive lympho-depleting chemotherapy
- Take the study drug
- Provide tumor tissue
- Have physical exams and blood draws
- Have imaging scans (CT and/or MRI)
- Have heart tests (ECG)
Study Details
Full Title
A Phase 1/2, Open-label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9–Engineered T Cells (CTX131) in Adult Subjects with Relapsed or Refractory Solid Tumors
Principal Investigator
Christopher
Hoimes
Protocol Number
PRO00112460
NCT ID
NCT05795595
Phase
I/II
Enrollment Status
Open to Enrollment